(CNC) Centene - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US15135B1017
Stock:
Total Rating 37
Risk 76
Buy Signal 0.44
| Risk 5d forecast | |
|---|---|
| Volatility | 49.2% |
| Relative Tail Risk | -11.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.16 |
| Alpha | -26.83 |
| Character TTM | |
|---|---|
| Beta | 0.127 |
| Beta Downside | 0.011 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.65% |
| CAGR/Max DD | -0.20 |
EPS (Earnings per Share)
Revenue
Description: CNC Centene
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: -6.67b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 6.16 > 1.0 |
| NWC/Revenue: 7.45% < 20% (prev 2.29%; Δ 5.16% < -1%) |
| CFO/TA 0.07 > 3% & CFO 5.09b > Net Income -6.67b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (491.1m) vs 12m ago -2.17% < -2% |
| Gross Margin: 12.24% > 18% (prev 0.10%; Δ 1213 % > 0.5%) |
| Asset Turnover: 243.3% > 50% (prev 197.8%; Δ 45.52% > 0%) |
| Interest Coverage Ratio: -9.46 > 6 (EBITDA TTM -5.14b / Interest Expense TTM 678.0m) |
Altman Z'' 1.21
| A: 0.19 (Total Current Assets 35.99b - Total Current Liabilities 21.48b) / Total Assets 77.66b |
| B: 0.11 (Retained Earnings 8.67b / Total Assets 77.66b) |
| C: -0.08 (EBIT TTM -6.42b / Avg Total Assets 80.05b) |
| D: 0.15 (Book Value of Equity 8.62b / Total Liabilities 57.60b) |
| Altman-Z'' Score: 1.21 = BB |
Beneish M -3.38
| DSRI: 0.77 (Receivables 18.11b/19.71b, Revenue 194.78b/163.07b) |
| GMI: 0.84 (GM 12.24% / 10.32%) |
| AQI: 0.99 (AQ_t 0.51 / AQ_t-1 0.51) |
| SGI: 1.19 (Revenue 194.78b / 163.07b) |
| TATA: -0.15 (NI -6.67b - CFO 5.09b) / TA 77.66b) |
| Beneish M-Score: -3.38 (Cap -4..+1) = AA |
What is the price of CNC shares?
As of March 02, 2026, the stock is trading at USD 44.88 with a total of 5,991,788 shares traded.
Over the past week, the price has changed by +3.55%, over one month by +4.86%, over three months by +18.45% and over the past year by -23.40%.
Over the past week, the price has changed by +3.55%, over one month by +4.86%, over three months by +18.45% and over the past year by -23.40%.
Is CNC a buy, sell or hold?
Centene has received a consensus analysts rating of 3.89.
Therefore, it is recommended to buy CNC.
- StrongBuy: 7
- Buy: 3
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CNC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.4 | -1.2% |
| Analysts Target Price | 44.4 | -1.2% |
CNC Fundamental Data Overview March 01, 2026
P/E Forward = 13.986
P/S = 0.1253
P/B = 1.0581
P/EG = 1.7255
Revenue TTM = 194.78b USD
EBIT TTM = -6.42b USD
EBITDA TTM = -5.14b USD
Long Term Debt = 17.35b USD (from longTermDebt, last quarter)
Short Term Debt = 196.0m USD (from shortTermDebt, last quarter)
Debt = 18.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 889.0m USD (from netDebt column, last quarter)
Enterprise Value = 22.96b USD (22.07b + Debt 18.78b - CCE 17.89b)
Interest Coverage Ratio = -9.46 (Ebit TTM -6.42b / Interest Expense TTM 678.0m)
EV/FCF = 5.31x (Enterprise Value 22.96b / FCF TTM 4.32b)
FCF Yield = 18.82% (FCF TTM 4.32b / Enterprise Value 22.96b)
FCF Margin = 2.22% (FCF TTM 4.32b / Revenue TTM 194.78b)
Net Margin = -3.43% (Net Income TTM -6.67b / Revenue TTM 194.78b)
Gross Margin = 12.24% ((Revenue TTM 194.78b - Cost of Revenue TTM 170.94b) / Revenue TTM)
Gross Margin QoQ = 15.18% (prev 16.38%)
Tobins Q-Ratio = 0.30 (Enterprise Value 22.96b / Total Assets 77.66b)
Interest Expense / Debt = 0.89% (Interest Expense 168.0m / Debt 18.78b)
Taxrate = 21.0% (US default 21%)
NOPAT = -5.07b (EBIT -6.42b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.68 (Total Current Assets 35.99b / Total Current Liabilities 21.48b)
Debt / Equity = 0.94 (Debt 18.78b / totalStockholderEquity, last quarter 19.95b)
Debt / EBITDA = -0.17 (negative EBITDA) (Net Debt 889.0m / EBITDA -5.14b)
Debt / FCF = 0.21 (Net Debt 889.0m / FCF TTM 4.32b)
Total Stockholder Equity = 24.06b (last 4 quarters mean from totalStockholderEquity)
RoA = -8.34% (Net Income -6.67b / Total Assets 77.66b)
RoE = -27.74% (Net Income TTM -6.67b / Total Stockholder Equity 24.06b)
RoCE = -15.49% (EBIT -6.42b / Capital Employed (Equity 24.06b + L.T.Debt 17.35b))
RoIC = -12.13% (negative operating profit) (NOPAT -5.07b / Invested Capital 41.78b)
WACC = 3.77% (E(22.07b)/V(40.85b) * Re(6.38%) + D(18.78b)/V(40.85b) * Rd(0.89%) * (1-Tc(0.21)))
Discount Rate = 6.38% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.43%
[DCF] Terminal Value 80.82% ; FCFF base≈4.32b ; Y1≈2.84b ; Y5≈1.29b
[DCF] Fair Price = 82.05 (EV 41.24b - Net Debt 889.0m = Equity 40.35b / Shares 491.8m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -53.28 | EPS CAGR: -54.28% | SUE: 0.08 | # QB: 0
Revenue Correlation: 92.73 | Revenue CAGR: 8.06% | SUE: 2.05 | # QB: 12
EPS next Quarter (2026-06-30): EPS=1.08 | Chg7d=+0.000 | Chg30d=+0.070 | Revisions Net=+3 | Analysts=17
EPS current Year (2026-12-31): EPS=2.97 | Chg7d=+0.000 | Chg30d=-0.021 | Revisions Net=+1 | Growth EPS=+42.7% | Growth Revenue=-3.1%
EPS next Year (2027-12-31): EPS=4.13 | Chg7d=+0.000 | Chg30d=+0.100 | Revisions Net=+1 | Growth EPS=+39.1% | Growth Revenue=+0.8%
[Analyst] Revisions Ratio: +0.27 (7 Up / 4 Down within 30d for Next Quarter)
P/S = 0.1253
P/B = 1.0581
P/EG = 1.7255
Revenue TTM = 194.78b USD
EBIT TTM = -6.42b USD
EBITDA TTM = -5.14b USD
Long Term Debt = 17.35b USD (from longTermDebt, last quarter)
Short Term Debt = 196.0m USD (from shortTermDebt, last quarter)
Debt = 18.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 889.0m USD (from netDebt column, last quarter)
Enterprise Value = 22.96b USD (22.07b + Debt 18.78b - CCE 17.89b)
Interest Coverage Ratio = -9.46 (Ebit TTM -6.42b / Interest Expense TTM 678.0m)
EV/FCF = 5.31x (Enterprise Value 22.96b / FCF TTM 4.32b)
FCF Yield = 18.82% (FCF TTM 4.32b / Enterprise Value 22.96b)
FCF Margin = 2.22% (FCF TTM 4.32b / Revenue TTM 194.78b)
Net Margin = -3.43% (Net Income TTM -6.67b / Revenue TTM 194.78b)
Gross Margin = 12.24% ((Revenue TTM 194.78b - Cost of Revenue TTM 170.94b) / Revenue TTM)
Gross Margin QoQ = 15.18% (prev 16.38%)
Tobins Q-Ratio = 0.30 (Enterprise Value 22.96b / Total Assets 77.66b)
Interest Expense / Debt = 0.89% (Interest Expense 168.0m / Debt 18.78b)
Taxrate = 21.0% (US default 21%)
NOPAT = -5.07b (EBIT -6.42b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.68 (Total Current Assets 35.99b / Total Current Liabilities 21.48b)
Debt / Equity = 0.94 (Debt 18.78b / totalStockholderEquity, last quarter 19.95b)
Debt / EBITDA = -0.17 (negative EBITDA) (Net Debt 889.0m / EBITDA -5.14b)
Debt / FCF = 0.21 (Net Debt 889.0m / FCF TTM 4.32b)
Total Stockholder Equity = 24.06b (last 4 quarters mean from totalStockholderEquity)
RoA = -8.34% (Net Income -6.67b / Total Assets 77.66b)
RoE = -27.74% (Net Income TTM -6.67b / Total Stockholder Equity 24.06b)
RoCE = -15.49% (EBIT -6.42b / Capital Employed (Equity 24.06b + L.T.Debt 17.35b))
RoIC = -12.13% (negative operating profit) (NOPAT -5.07b / Invested Capital 41.78b)
WACC = 3.77% (E(22.07b)/V(40.85b) * Re(6.38%) + D(18.78b)/V(40.85b) * Rd(0.89%) * (1-Tc(0.21)))
Discount Rate = 6.38% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.43%
[DCF] Terminal Value 80.82% ; FCFF base≈4.32b ; Y1≈2.84b ; Y5≈1.29b
[DCF] Fair Price = 82.05 (EV 41.24b - Net Debt 889.0m = Equity 40.35b / Shares 491.8m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -53.28 | EPS CAGR: -54.28% | SUE: 0.08 | # QB: 0
Revenue Correlation: 92.73 | Revenue CAGR: 8.06% | SUE: 2.05 | # QB: 12
EPS next Quarter (2026-06-30): EPS=1.08 | Chg7d=+0.000 | Chg30d=+0.070 | Revisions Net=+3 | Analysts=17
EPS current Year (2026-12-31): EPS=2.97 | Chg7d=+0.000 | Chg30d=-0.021 | Revisions Net=+1 | Growth EPS=+42.7% | Growth Revenue=-3.1%
EPS next Year (2027-12-31): EPS=4.13 | Chg7d=+0.000 | Chg30d=+0.100 | Revisions Net=+1 | Growth EPS=+39.1% | Growth Revenue=+0.8%
[Analyst] Revisions Ratio: +0.27 (7 Up / 4 Down within 30d for Next Quarter)